Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2010 pubmed 49 citations

Antimicrobial peptide rCRAMP induced glial cell activation through P2Y receptor signalling pathways.

Brandenburg. Lars-Ove LO; Jansen. Sandra S; Wruck. Christoph J CJ; Lucius. Ralph R; Pufe. Thomas T

Key Findings

  • rCRAMP/LL‑37 induces pro‑inflammatory cytokines and neurotrophic factors in astrocytes and microglia
  • Activation of signaling pathways like ERK1/2 is triggered by rCRAMP
  • The glial response is blocked by P2Y receptor antagonists, indicating P2Y11 involvement

Practical Outcomes

  • For biohackers, this suggests that taking LL‑37 could influence brain immune activity, potentially affecting inflammation or neuroprotection, but there’s no dosage guidance yet. It highlights the need for caution and further research before using LL‑37 as a brain‑targeted supplement.

Summary

The study shows that the antimicrobial peptide LL‑37 (called rCRAMP in rats) can activate brain support cells called glia, causing them to release inflammation signals and growth factors, and this effect works through a specific brain receptor (P2Y11).

Abstract

Antimicrobial peptides are part of the innate immune system of many organ systems, yet little is known about their expression and function in the brain. The antibacterial cathelicidin rCRAMP in rats (homologue of the human LL-37) not only exhibits potent bactericidal activities but also functions as a chemoattractant for immune cells. In this study, to further evaluate the role of rCRAMP in innate immunity of brain cells, we investigated the impact of rCRAMP on glial cell activation. To this end we analyzed the activation of rCRAMP-induced signalling by cytokine expression, Western blotting of certain signal transduction pathways and by cAMP level measurement in primary rat glial cells (astrocytes and microglia). We demonstrate (i) the induction of proinflammatory cytokine and neurotrophic factors and (ii) the activation of various signal transduction pathways by rCRAMP in glial cells. Moreover, (iii) we have been able to show that rCRAMP-induced IL-6 expression and ERK1/2 phosphorylation in glial cells were attenuated by the antagonists for purinergic receptor P2Y, whereas P2X and FPRL1 antagonists do not show any effects. Our results indicate for the first time that a newly identified P2Y11 receptor participates in rCRAMP-induced signal transduction. This study provides evidence that rCRAMP participates in brain immunity by stimulating cytokine production and glial cell activation, and aid in the protection of brain cells by inducing neurotrophic factors.

Study Information

Provider

pubmed

Year

2010

Date

2010-04-13T00:00:00.000Z

DOI

10.1016/j.molimm.2010.03.012

Citations

49

References

34